story of the week
Sugemalimab or Placebo Plus Chemotherapy as First-Line Treatment for Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Nat Cancer 2023 Jun 01;4(6)860-871, C Zhou, Z Wang, M Sun, L Cao, Z Ma, R Wu, Y Yu, W Yao, S Sun, J Chen, W Zhuang, J Cui, X Chen, Y Lu, H Shen, C Hu, J Liu, Y Liu, M Wang, X Li, P Sun, Y Shu, J Zhou, J Li, K Gu, C Wang, H Zhao, Y Zhang, C Liu, J Wang, R Chen, M Qin, H Wang, J YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.